Rsk-1

Isoforms Recommended:	RSK1

By Targets:	Ribosomal S6 Kinase (RSK) (8) Akt (1) Apoptosis (9) Autophagy (1) Checkpoint Kinase (Chk) (5) DNA/RNA Synthesis (1) DYRK (1) ERK (3) p38 MAPK (2) ROCK (1) YB-1 (1)
By Research Areas:	Cancer (16) Cardiovascular Disease (1) Inflammation/Immunology (2) Metabolic Disease (1)

Targets Recommended: Ribosomal S6 Kinase (RSK)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-113592

ERK-IN-4	ERK	Cancer
ERK-IN-4 is an ERK inhibitor binds preferentially to ERK2 with a K_d of 5 μM. ERK-IN-4 specificity inhibits ERK Rsk-1 and Elk-1 phosphorylation. ERK-IN-4 has little effect on ERK protein phosphorylation by its upstream activator MEK1/2 ^[1].

HY-19712

LJH685 2 Publications Verification	Ribosomal S6 Kinase (RSK) Apoptosis	Cancer
LJH685 is a potent, ATP-competitive and selective *RSK* inhibitor, inhibits RSK1, 2, and 3 biochemical activities with IC₅₀s of 6, 5, 4 nM, respectively ^[1].

HY-10510

BI-D1870 10+ Cited Publications	Ribosomal S6 Kinase (RSK) Autophagy	Cancer
BI-D1870 is an ATP-competitive, cell permeable and brain penetrated inhibitor of *RSK* isoforms, with IC₅₀s of 31 nM/24 nM/18 nM/15 nM for RSK1/RSK2/RSK3/RSK4, respectively ^[1] .

HY-14362

GSK-25	ROCK Ribosomal S6 Kinase (RSK)	Cardiovascular Disease
GSK-25 is a potent, selective and orally bioavailable *ROCK1* inhibitor (IC₅₀=7 nM). GSK-25 maintains good selectivity against a panel of 31 kinases (>100 fold), as well as RSK1 and p70S6K (RSK1: IC₅₀=398 nM, p70S6K: IC₅₀=1 μM). GSK-25 inhibits P450 profile (IC₅₀s of 2.5, 5.2, 2.5 µM for CYP2C9, CYP2D6, CYP3A4, respectively) ^[1].

HY-10579

Pluripotin SC1	Ribosomal S6 Kinase (RSK) ERK	Cancer
Pluripotin is a dual inhibitor of *ERK1* and RasGAP with K_Ds of 98 nM and 212 nM, respectively. Pluripotin also inhibits *RSK1, RSK2, RSK3, and RSK4* with IC₅₀s of 0.5, 2.5, 3.3, and 10.0 µM, respectively.

HY-12185

BRD7389 1 Publications Verification	Ribosomal S6 Kinase (RSK)	Metabolic Disease Cancer
BRD7389 is a specific *RSK* family kinase inhibitor with IC₅₀s of 1.5 μM, 2.4 μM, and 1.2 μM for *RSK1, RSK2, and RSK3*, respectively. BRD7389 is a small-molecule inducer of insulin expression in pancreatic α-cells ^[1].

HY-101494

Temuterkib Maximum Cited Publications 24 Publications Verification LY3214996	ERK	Cancer
Temuterkib (LY3214996) is a highly selective inhibitor of *ERK1* and ERK2, with IC₅₀ of 5 nM for both enzymes in biochemical assays. Temuterkib potently inhibits cellular p-RSK1 in BRAF and RAS mutant cancer cell lines. Temuterkib shows potent antitumor activities in cancer models with MAPK pathway alterations.

HY-114038

SB-747651A	p38 MAPK	Inflammation/Immunology
SB-747651A is an ATP-competitive mitogen- and stress-activated kinase 1 (MSK1) inhibitor with an IC₅₀ of 11 nM. SB-747651A also inhibits PRK2, RSK1, p70S6K and ROCK-II. SB-747651A can be used for inflammation research ^[1].

HY-110313

SB-747651A dihydrochloride	p38 MAPK	Inflammation/Immunology
SB-747651A dihydrochloride is an ATP-competitive mitogen- and stress-activated kinase 1 (MSK1) inhibitor with an IC₅₀ of 11 nM. SB-747651A dihydrochloride also inhibits PRK2, RSK1, p70S6K and ROCK-II. SB-747651A dihydrochloride can be used for inflammation research ^[1].

HY-15237

SL 0101-1 4 Publications Verification SL0101	Ribosomal S6 Kinase (RSK)	Cancer
SL 0101-1 (SL0101), a kaempferol glycoside, isolated from the tropical plant F. refracta, is a cell-permeable, selective, reversible, ATP-competitive p90 Ribosomal S6 Kinase (RSK) inhibitor, with an IC₅₀ of 89 nM ^[1]. SL 0101-1 (SL0101) is a selective *RSK1/2* inhibitor, with a K_i of 1 μM .

HY-18174

Prexasertib 15+ Cited Publications LY2606368	Checkpoint Kinase (Chk) Apoptosis	Cancer
Prexasertib (LY2606368) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a K_i of 0.9 nM and an IC₅₀ of <1 nM. Prexasertib inhibits CHK2 (IC₅₀=8 nM) and RSK1 (IC₅₀=9 nM). Prexasertib causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib shows potent anti-tumor activity ^[1] .

HY-18174A

Prexasertib dihydrochloride 15+ Cited Publications LY2606368 dihydrochloride	Checkpoint Kinase (Chk) Apoptosis	Cancer
Prexasertib dihydrochloride (LY2606368 dihydrochloride) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a K_i of 0.9 nM and an IC₅₀ of <1 nM. Prexasertib dihydrochloride inhibits CHK2 (IC₅₀=8 nM) and RSK1 (IC₅₀=9 nM). Prexasertib dihydrochloride causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib dihydrochloride shows potent anti-tumor activity ^[1] .

HY-19713

LJI308 4 Publications Verification	Ribosomal S6 Kinase (RSK) YB-1	Cancer
LJI308 is a potent pan-ribosomal S6 kinase (RSK) inhibitor, with IC₅₀s of 6 nM, 4 nM, and 13 nM for RSK1, RSK2, and RSK3, respectively. LJI308 inhibits the phosphorylation of RSK (T359/S363) and YB-1 (S102) after irradiation, treatment with EGF, and in cells expressing a KRAS mutation ^[1] .

HY-18174B

Prexasertib Mesylate Hydrate LY2606368 Mesylate Hydrate; LY2940930	Checkpoint Kinase (Chk) Apoptosis	Cancer
Prexasertib Mesylate Hydrate (LY2606368 Mesylate Hydrate) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a K_i of 0.9 nM and an IC₅₀ of <1 nM. Prexasertib Mesylate Hydrate inhibits CHK2 (IC₅₀=8 nM) and RSK1 (IC₅₀=9 nM). Prexasertib Mesylate Hydrate causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib Mesylate Hydrate shows potent anti-tumor activity ^[1] .

HY-18174C

Prexasertib mesylate LY2606368 mesylate	Checkpoint Kinase (Chk) DNA/RNA Synthesis Apoptosis	Cancer
Prexasertib mesylate (LY2606368 mesylate) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a K_i of 0.9 nM and an IC₅₀ of <1 nM. Prexasertib mesylate inhibits CHK2 (IC₅₀=8 nM) and RSK1 (IC₅₀=9 nM). Prexasertib mesylate causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib mesylate shows potent anti-tumor activity ^[1] .

HY-18174E

Prexasertib dimesylate 15+ Cited Publications LY2606368 dimesylate	Checkpoint Kinase (Chk) Apoptosis	Cancer
Prexasertib dimesylate (LY2606368 dimesylate) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a K_i of 0.9 nM and an IC₅₀ of <1 nM. Prexasertib dimesylate inhibits CHK2 (IC₅₀=8 nM) and RSK1 (IC₅₀=9 nM). Prexasertib dimesylate causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib dimesylate shows potent anti-tumor activity ^[1] .

HY-101029

MBM-55	Apoptosis	Cancer
MBM-55 is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 1 nM. MBM-55 shows a 20-fold or greater selectivity in most kinases with the exception of RSK1 (IC₅₀=5.4 nM) and DYRK1a (IC₅₀=6.5 nM). MBM-55 effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55 shows antitumor activities, and no obvious toxicity to mice ^[1].

HY-101029A

MBM-55S	Ribosomal S6 Kinase (RSK) DYRK Apoptosis	Cancer
MBM-55S is a potent NIMA-related kinase 2 (Nek2) inhibitor with an IC₅₀ of 1 nM. MBM-55S shows a 20-fold or greater selectivity in most kinases with the exception of RSK1 (IC₅₀=5.4 nM) and DYRK1a (IC₅₀=6.5 nM). MBM-55S effectively inhibits the proliferation of cancer cells by inducing cell cycle arrest and apoptosis. MBM-55S shows antitumor activities, and no obvious toxicity to mice ^[1].

HY-126257

AKT-IN-3	Akt Apoptosis	Cancer
AKT-IN-3 (compound E22) is a potent, orally active low hERG blocking Akt inhibitor, with 1.4 nM, 1.2 nM and 1.7 nM for Akt1, Akt2 and Akt3, respectively. AKT-IN-3 (compound E22) also exhibits good inhibitory activity against other AGC family kinases, such as PKA, PKC, ROCK1, RSK1, P70S6K, and SGK. AKT-IN-3 (compound E22) induces apoptosis and inhibits metastasis of cancer cells ^[1].

Cat. No.	Product Name	Target	Research Area

HY-P10042

S6K Substrate

Peptides Others

S6K Substrate is a substrate for active protein kinases, including CLK2, MRCKalpha, MRCKbeta, p70S6K, ROCK1, ROCK2, RSK1, RSK3, PIM1 ^[1].

S6K Substrate	Peptides	Others
S6K Substrate is a substrate for active protein kinases, including CLK2, MRCKalpha, MRCKbeta, p70S6K, ROCK1, ROCK2, RSK1, RSK3, PIM1 ^[1].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-15237

SL 0101-1 4 Publications Verification SL0101	Structural Classification Flavonols Flavonoids other families Classification of Application Fields Forsteronia refracta Plants Disease Research Fields Cancer	Ribosomal S6 Kinase (RSK)
SL 0101-1 (SL0101), a kaempferol glycoside, isolated from the tropical plant F. refracta, is a cell-permeable, selective, reversible, ATP-competitive p90 Ribosomal S6 Kinase (RSK) inhibitor, with an IC₅₀ of 89 nM ^[1]. SL 0101-1 (SL0101) is a selective *RSK1/2* inhibitor, with a K_i of 1 μM .

Species:	Human (2)
Tag:	His (1) Tag Free (1)
Source:	Sf9 insect cells (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P701771

	RSK1 Protein, Human (Sf9) RPS6KA1; Ribosomal protein S6 kinase alpha-1; S6K-alpha-1; 90 kDa ribosomal protein S6 kinase 1; p90-Rsk 1; p90Rsk1; p90S6K; MAP kinase-activated protein kinase 1a; MAPK-activated protein kinase 1a; MAPKAP kinase 1a; MAPKAPK-1a; Ribosomal S6 kinase 1; Rsk-1	Human	Sf9 insect cells
	RSK1 is a kinase downstream of ERK signaling and is critical for mitosis and stress-induced responses. It activates transcription factors (CREB1, ETV1, NR4A1), affecting proliferation, survival and differentiation. RSK1 Protein, Human (Sf9) is the recombinant human-derived RSK1 protein, expressed by Sf9 insect cells , with tag free. The total length of RSK1 Protein, Human (Sf9) is 321 a.a., .

HY-P701772

	RSK1 Protein, Human (Sf9, His) RPS6KA1; Ribosomal protein S6 kinase alpha-1; S6K-alpha-1; 90 kDa ribosomal protein S6 kinase 1; p90-Rsk 1; p90Rsk1; p90S6K; MAP kinase-activated protein kinase 1a; MAPK-activated protein kinase 1a; MAPKAP kinase 1a; MAPKAPK-1a; Ribosomal S6 kinase 1; Rsk-1	Human	Sf9 insect cells
	RSK1 is a kinase downstream of ERK signaling and is critical for mitosis and stress-induced responses. It activates transcription factors (CREB1, ETV1, NR4A1), affecting proliferation, survival and differentiation. RSK1 Protein, Human (Sf9, His) is the recombinant human-derived RSK1 protein, expressed by Sf9 insect cells , with N-8*His labeled tag. The total length of RSK1 Protein, Human (Sf9, His) is 321 a.a., .


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P80849

	*Phospho-RSK1* p90 (Thr359/Ser363) Antibody** RPS6KA1; MAPKAPK1A; Rsk1; Ribosomal protein S6 kinase alpha-1; S6K-alpha-1; 90 kDa ribosomal protein S6 kinase 1; p90-Rsk 1; p90Rsk1; p90S6K; MAP kinase-activated protein kinase 1a; MAPK-activated protein kinase 1a; MAPKAP kinase 1a; MAPKAP	WB, IP	Human, Mouse, Rat
	Phospho-RSK1 p90 (Thr359/Ser363) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 83 kDa, targeting to Phospho-RSK1 p90 (Thr359/Ser363). It can be used for WB,IP assays with tag free, in the background of Human, Mouse, Rat.

HY-P80848

	*Phospho-RSK1* p90 (Ser380) Antibody** RPS6KA1; MAPKAPK1A; Rsk1; Ribosomal protein S6 kinase alpha-1; S6K-alpha-1; 90 kDa ribosomal protein S6 kinase 1; p90-Rsk 1; p90Rsk1; p90S6K; MAP kinase-activated protein kinase 1a; MAPK-activated protein kinase 1a; MAPKAP kinase 1a; MAPKAP	WB, ICC/IF, IP	Human, Rat, Mouse
	Phospho-RSK1 p90 (Ser380) Antibody is a non-conjugated and Rabbit origined monoclonal antibody about 83 kDa, targeting to Phospho-RSK1 p90 (Ser380). It can be used for WB, ICC/IF, IP assays with tag free, in the background of Human, Mouse and Rat.

HY-P80315

	RSK1 p90 Antibody (YA088)	WB, ICC/IF, IHC-P, FC	Human, Mouse, Rat
	RSK1 p90 Antibody (YA088) is a non-conjugated and Rabbit origined monoclonal antibody about 83 kDa, targeting to RSK1 p90. It can be used for WB,ICC,IHC-P,FC assays with tag free, in the background of Human, Mouse, Rat.

HY-P80886

	RSK1 p90 Antibody (YA676) RPS6KA1; MAPKAPK1A; Rsk1; Ribosomal protein S6 kinase alpha-1; S6K-alpha-1; 90 kDa ribosomal protein S6 kinase 1; p90-Rsk 1; p90Rsk1; p90S6K; MAP kinase-activated protein kinase 1a; MAPK-activated protein kinase 1a; MAPKAP kinase 1a; MAPKAP	WB, IP	Human, Mouse, Monkey
	RSK1 p90 Antibody (YA676) is a non-conjugated and Mouse origined monoclonal antibody about 83 kDa, targeting to RSK1 p90 (6B9). It can be used for WB,IP assays with tag free, in the background of Human, Mouse, Monkey.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Peptides

Natural
Products

Recombinant Proteins

Antibodies

Name
Email *

	Sorry, but the email address you supplied was invalid.

Rsk-1

Inhibitors & Agonists

Peptides

NaturalProducts

Recombinant Proteins

Antibodies

Natural
Products